Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Alexion Pharmaceuticals | Eculizumab | Soliris |  | 2007-03-16 | $4,068.9 M | Q2/20-Q1/21 |
Ravulizumab | Ultomiris |  | 2019-07-02 | $1,200.8 M | Q2/20-Q1/21 | |
Amgen | Eculizumab | Bekemv |  | 2023-04-19 |  |  |
Orphan Medical | Pegcetacoplan | Aspaveli |  | 2021-12-13 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|